Which hematological cancer patients are suitable for acotinib/acalatinib?

Acalabrutinib/Acalabrutinib (Acalabrutinib): is a new generation Bruton’s tyrosine kinase (BTK) inhibitor, designed to more accurately target the BTK signaling pathway in B cell malignancies and reduce the impact on non-targeted kinases. The main indication of this drug is to treat specific types of hematological tumors derived from B cells. It is currently mainly used in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma (MCL).

In CLL and SLL, acotinib can be used in both treatment-naïve patients and relapsed patients after failure of frontline therapy. It is especially suitable for patients who are intolerant to first-generation BTK inhibitors such as ibrutinib or who interrupt treatment due to side effects. For patients with MCL, acotinib is usually used when they have relapsed or have received more than one treatment regimen, especially to provide a new treatment option for those whose disease is poorly controlled. Compared with previous drugs, acotinib has higher BTK selectivity, avoids the inhibition of other kinases such as EGFR and ITK, and reduces the risk of some adverse reactions.

Research and clinical observations have also found that the drug shows wider adaptability in combination treatment regimens, such as combined application with obinutuzumab (anti-CD20 monoclonal antibody), bendamustine or rituximab, which can further enhance efficacy and improve disease response. It should be emphasized that the use of acotinib should still be based on genetic testing, pathological type and individualized assessment. Doctors usually comprehensively judge whether the patient is suitable for using acotinib based on the patient's mutation status, treatment history and systemic condition.

In general, acotinib, as a new generation of BTK inhibitors, is gradually becoming an important treatment option for patients with B-cell malignant hematological tumors, especially for those who pursue lower side effects and personalized treatment strategies.

Reference materials:https://www.calquence.com/